<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02142751</url>
  </required_header>
  <id_info>
    <org_study_id>FOREST</org_study_id>
    <nct_id>NCT02142751</nct_id>
  </id_info>
  <brief_title>Fosfomycin Versus Meropenem or Ceftriaxone in Bacteriemic Infections Caused by Multidrug Resistance in E.Coli</brief_title>
  <acronym>FOREST</acronym>
  <official_title>Phase 3, Randomized, Controlled Multicentric, Open-label Clinical Trial to Prove Non-Inferiority of Fosfomycin vs Meropenem or Ceftriaxone in the Treatment of Bacteriemic Urinary Infection Due to Multidrug Resistance in E.Coli</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación Pública Andaluza para la gestión de la Investigación en Sevilla</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Spanish Network for Research in Infectious Diseases</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundación Pública Andaluza para la gestión de la Investigación en Sevilla</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Enterobacterieaceae (and specially Escherichia coli) showing resistance due to
      multidrug-resistant Escherichia coli, plasmid mediated AmpC or quinolone resistance caused by
      chromosomal mechanisms have spread worldwide during the last decades. This is important
      because many of these isolates are also resistant to other first-line agents such as
      fluoroquinolones or aminoglycosides, leaving few available options for therapy, and this
      condition is associated with increased morbidity- mortality and length of hospital stay.
      While carbapenems are considered the drugs of choice for multidrug-resistant Escherichia coli
      and AmpC producers, recent data suggests that certain alternatives may be suitable for some
      types of infections.

      At the present time, finding therapeutic alternatives to carbapenems and cephalosporins for
      the treatment of invasive infections due to multidrug-resistant Escherichia coli is critical.
      Fosfomycin was discovered more than 40 years ago but was not investigated according to
      present standards, and thus is not used in clinical practice except in desperate situations.
      It is one of the so-considered neglected antibiotics with high potential interest for the
      future.

      With the aim of demonstrate the clinical non-inferiority of intravenous fosfomycin compared
      to meropenem or ceftriaxone in the treatment of bacteraemic urinary tract infections caused
      by multidrug-resistant Escherichia coli . The investigators propose a &quot;real practise&quot;
      randomised, controlled, multicentre phase III clinical trial to compare the clinical and
      microbiological efficacy and safety of intravenous fosfomycin (4 grammes every 6 hours) with
      meropenem (1 gramme every 8 hours) or ceftriaxone (1 gramme every 24 hours) as targeted
      therapy of the previously specified infection; change to oral therapy according to predefined
      options is allowed in both arms after 5 days. Follow-up for the study is planned up to 60
      days.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The FOREST study is a phase 3, randomised, controlled, multicentric, open-label clinical
      trial to prove the noninferiority of fosfomycin versus meropenem in the targeted treatment of
      bacteraemic UTI due to ESBL-EC, designed as a real practice trial. It is a non-commercial,
      investigator-driven clinical study funded through a public competitive call by Instituto de
      Salud Carlos III, Spanish Ministry of Economy (PI13/01282).

      The study is coordinated by investigators from Hospital Universitario Virgen Macarena in
      Seville, Spain; the sponsorship is performed by Fundación Pública Andaluza para la Gestión de
      la Investigación en Salud de Sevilla (FISEVI), of which the sponsor-scientific
      responsibilities are delegated to the CTU (Clinical Trial Unit—Hospital Universitario Virgen
      del Rocío, Seville, Spain). All participating patients or their relatives must give written
      informed consent before any study procedures occur, including the withdrawal of biological
      samples for the study.

      The hypothesis to test is that intravenous fosfomycin is not inferior to meropenem for the
      targeted treatment of bacteraemic UTI caused by ESBL-EC in terms of efficacy.

      The primary objective of the study is to demonstrate that intravenous fosfomycin is not
      inferior to meropenem for reaching clinical and microbiological cure 5-7 days after the
      completion of treatment.

      Secondary objectives include comparing the early clinical and microbiological response,
      30-day mortality, hospital stay, recurrence rate, safety and impact on intestinal
      colonisation by MDR Gram-negative bacilli, evaluation of the rate of resistance development
      to fosfomycin and blood level concentration of fosfomycin.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical and microbiological cure rate</measure>
    <time_frame>Day 5-7 after end of treatment (test of cure)</time_frame>
    <description>Clinical Cure: Complete resolution of infection symptoms (bacteremia and/or urinary tract infection-UTI-), present at the day on which blood culture was drawn.
Microbiological cure: Negative blood culture at day 5-7 after end of treatment. Besides this, if UTI was confirmed with a positive urine culture with the same microorganism than the blood culture, this culture should become negative.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Early clinical response</measure>
    <time_frame>After 5 -7 days of complete treatment (from the first day of study drugs administration)</time_frame>
    <description>The infection was completely resolved after 5-7 days of complete treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>At day 30 of follow-up</time_frame>
    <description>Death for any reason.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>At day 30 of follow-up</time_frame>
    <description>It is defined as the time from admission to hospital discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of intravenous fosfomycin in this indication</measure>
    <time_frame>To the last visit, at 60 plus-minus 10 days (from the first day of study drugs administration)</time_frame>
    <description>Gathering any related adverse event from the informed consent form signature to the end of follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrences (relapse and reinfection) rate</measure>
    <time_frame>To the last visit, at 60 plus-minus 10 days (from the first day of study drugs administration)</time_frame>
    <description>Relapse: new symptoms of UTI in patient with previously considered as clinical or microbiological cured in the visit of day 5-7 plus positive urine or blood cultures with the same microorganism isolated than the initial culture.
Re-infection: same definition but with different strain in the culture results.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fosfomycin steady-state plasma concentration</measure>
    <time_frame>At 3 days after treatment started</time_frame>
    <description>Therapeutic drug monitoring of fosfomycin, basic pharmacokinetic parameters will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiota impact of study treatment bacilli</measure>
    <time_frame>Screening, day 5-7, day 12</time_frame>
    <description>Study treatment impact in the gut colonization of MDRGNB (Multi drug resistant Gram negative bacilli)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Emergence of resistant clinical isolates of Escherichia coli to fosfomycin and meropenem</measure>
    <time_frame>participants will be followed for the duration of fosfomycin, an expected average of 14 days</time_frame>
    <description>Frequency of strains that develop resistance and detection of resistance mechanisms in fosfomycin treatment arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early microbiological response</measure>
    <time_frame>within the first 5 days after treatment started</time_frame>
    <description>Cultures are negative</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of intravenous antibiotic administration in this indication</measure>
    <time_frame>To the last visit, at 60 plus-minus 10 days (from the first day of study drugs administration)</time_frame>
    <description>Gathering any related adverse event from the informed consent form signature to the end of follow-up.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">198</enrollment>
  <condition>Infection Due to ESBL Escherichia Coli</condition>
  <arm_group>
    <arm_group_label>Fosfomycin sodium intravenous</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4g every 6 hours iv (60 min infusion)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Meropenem intravenous</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1g every 8 hours (15-30 min infusion)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ceftriaxone intravenous</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>1g every 24h (2-4 min)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fosfomycin sodium intravenous</intervention_name>
    <description>4g every 6 hours iv (60 min infusion)</description>
    <arm_group_label>Fosfomycin sodium intravenous</arm_group_label>
    <other_name>Generic name: Fosfomycin</other_name>
    <other_name>Pharmaceutical form: solution for infusion</other_name>
    <other_name>ATC code: J01J3</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meropenem intravenous</intervention_name>
    <description>1g every 8 hours (15-30 min infusion) It depends on strain sensitivity: Strain with resistance to cephalosporins</description>
    <arm_group_label>Meropenem intravenous</arm_group_label>
    <other_name>Generic name: Meropenem</other_name>
    <other_name>Pharmaceutical form: solution for infusion</other_name>
    <other_name>ATC code: J01D5</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ceftriaxone intravenous</intervention_name>
    <description>1g every 24 hours iv (2-4 min infusion) It depends on strain sensitivity: Strain with resistance to quinolone but sensitivity to cephalosporins</description>
    <arm_group_label>Ceftriaxone intravenous</arm_group_label>
    <other_name>generic name: ceftriaxone</other_name>
    <other_name>Pharmaceutical form: solution for infusion</other_name>
    <other_name>ATC code:J01DA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥18 years old hospitalized patients

          -  Negative pregnancy test in fertile women

          -  Episode of clinically-significant monomicrobial urinary BSI due to multidrug-resistant
             E.coli susceptible to fosfomycin and meropenem or ceftriaxone

          -  Urinary sepsis with multidrug resistant E. coli isolation from the blood cultures,
             requires at least one clinical criteria and one of the following urinalysis criteria:

        Clinical criteria

          -  UTI symptoms (dysuriac, urgency, suprapubic pain or pollakiuria)

          -  Lumbar back pain

          -  Cost-vertebral angle tenderness

          -  Altered mental status in people up to 70 years old

          -  Intermittent or permanent indwelling foley catheter (or withdrawal during 24 hours
             previous) even without urinary symptoms urinalysis criteria

          -  Urine dipstick test positive for either nitrites or leukocyte esterase

          -  Positive urine culture - Signed informed consent form (ICF) executed prior to protocol
             screening assessments

        Exclusion Criteria:

          -  Polymicrobial bacteremia

          -  No drainage of renal abscess or obstructive uropathy unresolved

          -  Pregnant or careening women

          -  Haematogenous infection

          -  Other concomitant infection

          -  Renal transplantation recipients

          -  Polycystic kidney

          -  Hypersensitivity and/or intolerance to meropenem or fosfomycin or ceftriaxone

          -  Palliative care or life expectance &lt; 90 days

          -  Septic shock at time of randomization

          -  New York Heart Association (NYHA) functional Class IV, hepatic cirrhosis or renal
             impairment receiving dialysis

          -  Active empiric treatment &gt;72 hours

          -  Late randomization &gt;24 hours after multidrug resistant.coli blood culture´s
             identification

          -  Participation in other clinical trial with active treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>JESUS RODRIGUEZ-BAÑO, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Spanish Network for Research in Infectious Diseases</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clara M. Rosso Fernández, MD, PhD</last_name>
    <phone>+34955013414</phone>
    <email>claram.rosso.sspa@juntadeandalucia.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eva Recio Sánchez, BS,PhD</last_name>
    <email>eva.recio.exts@juntadeandalucia.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Mutua de Terrassa</name>
      <address>
        <city>Terrassa</city>
        <state>Barcelona</state>
        <zip>08221</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ester Calbo, MDPhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Gran Canaria Dr. Negrín</name>
      <address>
        <city>Las Palmas De Gran Canaria</city>
        <state>Gran Canarias</state>
        <zip>35010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Miguel Angel Cárdenas Santana, MDPhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Arnau de Vilanova</name>
      <address>
        <city>Vilanova</city>
        <state>Lleida</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Alfredo Jover, MDPhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario Virgen de la Arrixaca</name>
      <address>
        <city>El Palmar</city>
        <state>Murcia</state>
        <zip>30120</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Alicia Hernández Torres, MDPhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Canarias</name>
      <address>
        <city>La Laguna</city>
        <state>Tenerife</state>
        <zip>38320</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>María Lecuona Fernández, MDPhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Marina Baixa</name>
      <address>
        <city>Alicante</city>
        <zip>03010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Concepción Amador Prous, MDPhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Alicante</name>
      <address>
        <city>Alicante</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Vicente Voix Martínez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Parc Salud Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>María Luisa Sorli Redó, MDPhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i San Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Virginia Pomar Solchaga, MDPhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Carlos Pigrau Serrallach, MDPhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Bellvitge</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Evelyn Shaw Perujo, MDPhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Cruces</name>
      <address>
        <city>Bilbao</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena Bereciartua, MD.PhD</last_name>
      <email>ELENA.BERECIARTUABASTARRICA@osakidetza.net</email>
    </contact>
    <investigator>
      <last_name>Miguel Montejo, MD.PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elena ELENA.BERECIARTUABASTARRICA@osakidetza.net, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Burgos</name>
      <address>
        <city>Burgos</city>
        <zip>09006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofía</name>
      <address>
        <city>Córdoba</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clara Natera, MD, PhD</last_name>
      <email>clrntr@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Clara Natera, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Vicente Pintado García, MDPhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>José Tiago Sequeira López da Silva, MDPhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Central de Asturias</name>
      <address>
        <city>Oviedo</city>
        <zip>33006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Hospital Son Espases</name>
      <address>
        <city>Palma de Mallorca</city>
        <zip>07010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Hospital Marqués de Valdecilla</name>
      <address>
        <city>Santander</city>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Luis Martínez Martínez, MDPhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen Macarena</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jesús Sojo Dorado, MD</last_name>
      <phone>+34 955009024</phone>
      <email>jesodo@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Adoración Valiente</last_name>
    </contact_backup>
    <investigator>
      <last_name>Jesús Sojo Dorado, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zaira R Palacios Baena, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vicente Merino Bohorquez</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Adoración Valiente, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario y Politécnico La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Hospital Royo Villanova</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.reipi.org/</url>
    <description>Spanish Network Research in Infectious Diseases (Red Española de Investigación en Patología Infecciosa [REIPI])</description>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 13, 2014</study_first_submitted>
  <study_first_submitted_qc>May 16, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2014</study_first_posted>
  <last_update_submitted>April 26, 2018</last_update_submitted>
  <last_update_submitted_qc>April 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Escherichia coli</keyword>
  <keyword>Extended-spectrum β-lactamases (ESBLs)</keyword>
  <keyword>Bacteremia</keyword>
  <keyword>Urinary tract infection</keyword>
  <keyword>Bloodstream infection</keyword>
  <keyword>Fosfomycin</keyword>
  <keyword>Meropenem</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>intestinal colonization</keyword>
  <keyword>Recurrence</keyword>
  <keyword>multidrug resistance E.coli</keyword>
  <keyword>Ceftriaxone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Ceftriaxone</mesh_term>
    <mesh_term>Meropenem</mesh_term>
    <mesh_term>Thienamycins</mesh_term>
    <mesh_term>Fosfomycin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

